SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Avalyn Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Initiated Phase 1 study of AP03, a fixed dose combination of nebulized pirfenidone and nintedanib, i

AVLN

Related stories